110 results on '"Colombo, Massimo"'
Search Results
2. IFNL4 rs368234815 and rs117648444 variants predict off‐treatment HBsAg seroclearance in IFN‐treated HBeAg‐negative chronic hepatitis B patients
3. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B
4. Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment
5. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus‐related cirrhosis who attained sustained virological response
6. Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study
7. Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis
8. Management of biliary anastomotic strictures after liver transplantation (BASALT study): A nationwide Italian survey
9. Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial
10. Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression?
11. A therapeutic conundrum: Delaying ablation of small nonresectable early hepatocellular carcinoma to facilitate liver transplantation
12. DEPDC5 Variants Increase Fibrosis Progression in Europeans with Chronic Hepatitis C Virus Infection
13. Treatment of hepatocellular carcinoma: beyond international guidelines
14. Natural Killer Cell Phenotype Modulation and Natural Killer/T-Cell Interplay in Nucleos(t)ide Analogue-Treated Hepatitis e Antigen-Negative Patients With Chronic Hepatitis B
15. Transarterial Chemoembolization With Drug-Eluting Beads Is Effective for the Maintenance of the Milan-In Status in Patients With a Small Hepatocellular Carcinoma
16. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)
17. Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma
18. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
19. Transient elastography spleen stiffness measurements in primary myelofibrosis patients: a pilot study in a single centre
20. Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib
21. A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration
22. Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients
23. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B
24. Cash from the crowd
25. Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication?
26. Treatment of hepatocellular carcinoma: beyond international guidelines
27. Interferon–ribavirin therapy induces serum antibodies determining ‘rods and rings’ pattern in hepatitis C patients
28. Hepatocellular Carcinoma Screening and Diagnosis
29. Timing of hepatocellular carcinoma (HCC) development and predictability of a modified PAGE-B risk score in caucasian chronic hepatitis B (CHB) patients treated with entecavir (ETV) or tenofovir (TDF): 233
30. Vitamin D deficiency and liver cancer: More than just an epidemiological association?
31. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study
32. Treatment of patients with dual hepatitis B and C: a step in the right direction
33. Impact of HBV therapy on the incidence of hepatocellular carcinoma
34. Stakeholder perspectives on European priorities for comprehensive liver cancer control: a conjoint analysis
35. Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B
36. PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history
37. Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound
38. Low rates of naturally occurring resistant variants to the NS5A inhibitor daclatasvir in HCV-1 null responders
39. Studies of IL28B genotype and response to peginterferon in chronic hepatitis B should be stratified by HBV genotype
40. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma
41. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen–negative patients with chronic hepatitis B
42. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?
43. Shaping the Future Management of Hepatocellular Carcinoma
44. Is there need for more than one IL28B single nucleotide polymorphism in hepatitis C clinical practice?
45. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C
46. Observations of Hepatocellular Carcinoma (HCC) Management Patterns from the Global HCC BRIDGE Study: Global Comparison of Outcomes by Locoregional Therapy: 1940
47. The ENT1 polymorphism is not associated with anemia in HCV patients receiving pegylated interferon plus ribavirin, but identifies a subgroup of highly responsive HCV genotype 1/4 IL28B CC patients: 1728
48. Transarterial chemoembolization with drug-eluting beads (DEB TACE) for BCLC-A hepatocellular carcinoma (HCC): a radical option?: 588
49. Prospective validation of 2010 AASLD guideline for the diagnosis of 1-2cm HCC in cirrhotic patients: 520
50. Switching to tenofovir is safe in most chronic hepatitis B patients with a reduced glomerular filtration rate due to previous exposure to adefovir dipivoxil: 406
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.